TITLE

Treating Itch in Psoriasis

AUTHOR(S)
Dawn, Aerlyn; Yosipovitch, Gil
PUB. DATE
June 2006
SOURCE
Dermatology Nursing;Jun2006, Vol. 18 Issue 3, p227
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a study on the effective management and treatment of psoriatic itch. Patients with chronic pruritus often have difficulty sleeping, problems concentrating, lowered sex drive, and depression. The treatments recommended for psoriatic itch are tar products, topical corticosteroids, topical salicylates, agents that alter skin sensation, phototherapy, vitamin D analogs, topical immunomodulators, methotrexate, oral mirtazapine, and biologics.
ACCESSION #
21110278

 

Related Articles

  • tazarotene.  // Royal Society of Medicine: Medicines;2002, p523 

    The article presents information on tazarotene which is chemically a derivative of retinol or vitamin A. This drug can be used to treat mild to moderate plaque psoriasis. Administration is by topical application. It should not be used in pregnancy or breast-feeding. Patients should wash hands...

  • Offer systemic therapy as first-line defense. Rutledge, Barbara J. // Dermatology Times;Sep2005 Supplement 4, Vol. 25, pS16 

    Evaluates the efficacy of alefacept therapy as first-line defense for psoriasis. Impact of psoriasis on the quality of life of the patient; Number of people affected with the disease of the year; Treatment paradigms for psoriasis.

  • Easing trepidation about biologies. Kapes, Beth // Dermatology Times;Sep2004 Supplement, Vol. 25, pS27 

    Discusses the benefits offered by biologics for psoriasis treatment. Affirmation of David E. Cohen that the new biologic products offer advantages over existing medications; Presentation of new biologics that are approved for treating moderate to sever psoriasis and psoriatic arthritis;...

  • Physician says TNF-a antagonists very safe, overall. Guttman, Cheryl // Dermatology Times;Sep2004 Supplement, Vol. 25, pS33 

    Reports that TNF-a antagonists are safe for psoriatic patients. Presentation of several antagonists safe for psoriatic therapy; Discussion on the risks of serious infections and malignancies related to the immunosuppressive activity of the TNF-a antagonist; Effects on patients after treated with...

  • Biologies for psoriasis pulling their weight. Wilson, Fred // Dermatology Times;Sep2004 Supplement, Vol. 25, pS18 

    The article discusses the effect of biologic therapy on psoriatic patients. Consideration of Amevive as the first biologic drug approved for moderate to severe plaque psoriasis; Elaboration on the effects of the drug, Raptiva; Responses of patients to Remicade infusions.

  • Study shows leading drugs' effectiveness against psoriasis. Jesitus, John // Dermatology Times;Sep2004 Supplement, Vol. 25, pS34 

    The article discusses the effectiveness of leading drugs against psoriasis. Statement of Craig L. Leonardi, associate dermatologist of St. Louis University in Missouri, on the effectiveness of Biogen's alefacept; Clarifications on the length of effectiveness of some drugs; Discussion on the...

  • new drugs for psoriasis might be lifesavers. Steinmehl, Eric; Martin, Adam // Health (Time Inc. Health);Mar2004, Vol. 18 Issue 2, p68 

    Provides information on biologics, a drug for treating psoriasis. Annual cost of the treatment; Percentage of people with psoriasis who consider committing suicide; Description of psoriasis.

  • Patient Profiles in Psoriatic Disease: A Case-Based Approach.  // Dermatology Nursing;Oct2007 Supplement, Vol. 19, p5 

    The article cites a study that describes the basic characteristics of psoriatic disease, a dermatologic disorder that affects residents in the U.S. It discusses the need for appropriate management for early and aggressive intervention of this condition. It highlights the principles that...

  • DERMATOLOGICAL DISORDERS.  // Monthly Prescribing Reference;Feb2011, Vol. 27 Issue 2, p122 

    A part of the book "Monthly Prescribing Reference" for February 2011 is presented. It offers an overview of pharmacological treatments for dermatological disorders including acne, psoriasis and skin infections. The drugs include Aczone from Allergan, Neoral from Novartis and Abreva from...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics